NCT06311227 2026-03-19
Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
13 trialsNCT01841723 2026-03-18
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06561360 2026-03-18
A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05537766 2026-03-10
ZUMA-25
Gilead Sciences
Phase 2 Terminated
NCT05283720 2026-03-03
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT03410875 2026-02-12
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT00412594 2025-12-22
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04324112 2025-11-10
Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT01711632 2025-10-20
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04322383 2025-08-26
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT00923013 2025-08-08
Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT01059786 2025-06-12
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT05388123 2025-05-29
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Scripps Health
Phase 2 Active not recruiting